Stephens Inc. AR Boosts Stock Position in Repligen Corporation $RGEN

Stephens Inc. AR lifted its position in Repligen Corporation (NASDAQ:RGEN) by 2.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 47,594 shares of the biotechnology company’s stock after buying an additional 1,359 shares during the quarter. Stephens Inc. AR’s holdings in Repligen were worth $5,920,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. KBC Group NV raised its holdings in shares of Repligen by 14.9% in the 1st quarter. KBC Group NV now owns 2,544 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 329 shares during the period. Harvest Fund Management Co. Ltd purchased a new stake in shares of Repligen in the 1st quarter valued at $132,000. XTX Topco Ltd raised its holdings in shares of Repligen by 34.2% in the 1st quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company’s stock valued at $1,646,000 after buying an additional 3,295 shares during the period. GAMMA Investing LLC raised its holdings in shares of Repligen by 40.1% in the 1st quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 274 shares during the period. Finally, Dynamic Technology Lab Private Ltd raised its holdings in shares of Repligen by 233.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 9,208 shares of the biotechnology company’s stock valued at $1,172,000 after buying an additional 6,448 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on RGEN. Hsbc Global Res upgraded Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. Jefferies Financial Group cut their price target on Repligen from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Friday, September 12th. Stephens upgraded Repligen to an “overweight” rating and set a $160.00 price target on the stock in a report on Tuesday, July 22nd. Barclays upped their price target on Repligen from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Thursday, October 2nd. Finally, Wall Street Zen downgraded Repligen from a “buy” rating to a “hold” rating in a report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $169.62.

Repligen Trading Up 1.4%

RGEN opened at $156.75 on Wednesday. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company has a market cap of $8.82 billion, a P/E ratio of -626.97, a PEG ratio of 3.42 and a beta of 1.08. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. The business’s 50-day simple moving average is $130.37 and its 200-day simple moving average is $126.83.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business had revenue of $182.37 million during the quarter, compared to analysts’ expectations of $174.62 million. During the same quarter in the previous year, the company posted $0.40 EPS. The company’s revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, equities research analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Martin D. Madaus acquired 1,800 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director owned 1,800 shares in the company, valued at $201,834. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.